Northern Trust’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41.8K | Buy |
5,583
+956
| +21% | +$10.1K | ﹤0.01% | 4288 |
|
|
2026
Q1 | $52.4K | Hold |
4,627
| – | – | ﹤0.01% | 4236 |
|
|
2025
Q4 | $59.2K | Buy |
4,627
+49
| +1% | +$754 | ﹤0.01% | 4246 |
|
|
2025
Q3 | $85.5K | Hold |
4,578
| – | – | ﹤0.01% | 4174 |
|
|
2025
Q2 | $117K | Hold |
4,578
| – | – | ﹤0.01% | 4080 |
|
|
2025
Q1 | $91.6K | Hold |
4,578
| – | – | ﹤0.01% | 4135 |
|
|
2024
Q4 | $83.3K | Buy |
4,578
+835
| +22% | +$16.4K | ﹤0.01% | 4190 |
|
|
2024
Q3 | $112K | Hold |
3,743
| – | – | ﹤0.01% | 4022 |
|
|
2024
Q2 | $52.6K | Sell |
3,743
-8
| -0.2% | -$139 | ﹤0.01% | 4202 |
|
|
2024
Q1 | $71.3K | Hold |
3,751
| – | – | ﹤0.01% | 4165 |
|
|
2023
Q4 | $83.3K | Hold |
3,751
| – | – | ﹤0.01% | 4150 |
|
|
2023
Q3 | $141K | Hold |
3,751
| – | – | ﹤0.01% | 3925 |
|
|
2023
Q2 | $269K | Buy |
3,751
+68
| +2% | +$4.3K | ﹤0.01% | 3713 |
|
|
2023
Q1 | $248K | Buy |
3,683
+116
| +3% | +$6.96K | ﹤0.01% | 3759 |
|
|
2022
Q4 | $111K | Hold |
3,567
| – | – | ﹤0.01% | 4061 |
|
|
2022
Q3 | $97K | Sell |
3,567
-12
| -0.3% | -$469 | ﹤0.01% | 4121 |
|
|
2022
Q2 | $157K | Sell |
3,579
-14,541
| -80% | -$668K | ﹤0.01% | 4010 |
|
|
2022
Q1 | $1.16M | Sell |
18,120
-843
| -4% | -$60.4K | ﹤0.01% | 3358 |
|
|
2021
Q4 | $1.59M | Sell |
18,963
-161
| -0.8% | -$18.1K | ﹤0.01% | 3337 |
|
|
2021
Q3 | $3.11M | Sell |
19,124
-1,157
| -6% | -$188K | ﹤0.01% | 3040 |
|
|
2021
Q2 | $3.06M | Sell |
20,281
-1,069
| -5% | -$180K | ﹤0.01% | 3138 |
|
|
2021
Q1 | $3.71M | Sell |
21,350
-1,506
| -7% | -$287K | ﹤0.01% | 2926 |
|
|
2020
Q4 | $3.64M | Buy |
22,856
+98
| +0.4% | +$16.4K | ﹤0.01% | 2856 |
|
|
2020
Q3 | $3.63M | Buy |
22,758
+4,795
| +27% | +$865K | ﹤0.01% | 2734 |
|
|
2020
Q2 | $3.56M | Buy |
17,963
+518
| +3% | +$95.1K | ﹤0.01% | 2729 |
|
|
2020
Q1 | $2.7M | Sell |
17,445
-693
| -4% | -$70K | ﹤0.01% | 2679 |
|
|
2019
Q4 | $1.4M | Sell |
18,138
-153
| -0.8% | -$13.3K | ﹤0.01% | 3288 |
|
|
2019
Q3 | $1.84M | Buy |
18,291
+569
| +3% | +$66.2K | ﹤0.01% | 3144 |
|
|
2019
Q2 | $2.34M | Buy |
17,722
+292
| +2% | +$40.1K | ﹤0.01% | 2993 |
|
|
2019
Q1 | $2.64M | Sell |
17,430
-229
| -1% | -$35.7K | ﹤0.01% | 2908 |
|
|
2018
Q4 | $2.85M | Sell |
17,659
-382
| -2% | -$75.9K | ﹤0.01% | 2853 |
|
|
2018
Q3 | $4.66M | Buy |
18,041
+2,578
| +17% | +$646K | ﹤0.01% | 2721 |
|
|
2018
Q2 | $3.53M | Buy |
15,463
+13,057
| +543% | +$2.47M | ﹤0.01% | 2883 |
|
|
2018
Q1 | $339K | Hold |
2,406
| – | – | ﹤0.01% | 3673 |
|
|
2017
Q4 | $313K | Sell |
2,406
-32
| -1% | -$4.07K | ﹤0.01% | 3674 |
|
|
2017
Q3 | $302K | Buy |
2,438
+596
| +32% | +$60.8K | ﹤0.01% | 3674 |
|
|
2017
Q2 | $158K | Hold |
1,842
| – | – | ﹤0.01% | 3871 |
|
|
2017
Q1 | $166K | Buy |
1,842
+613
| +50% | +$68.5K | ﹤0.01% | 3838 |
|
|
2016
Q4 | $134K | Buy |
1,229
+44
| +4% | +$4.82K | ﹤0.01% | 3837 |
|
|
2016
Q3 | $152K | Hold |
1,185
| – | – | ﹤0.01% | 3803 |
|
|
2016
Q2 | $108K | Hold |
1,185
| – | – | ﹤0.01% | 3872 |
|
|
2016
Q1 | $93K | Hold |
1,185
| – | – | ﹤0.01% | 3920 |
|
|
2015
Q4 | $132K | Hold |
1,185
| – | – | ﹤0.01% | 3871 |
|
|
2015
Q3 | $150K | Buy |
1,185
+208
| +21% | +$27.7K | ﹤0.01% | 3828 |
|
|
2015
Q2 | $120K | Buy |
977
+223
| +30% | +$30.3K | ﹤0.01% | 3912 |
|
|
2015
Q1 | $199K | Buy |
+754
| New | +$155K | ﹤0.01% | 3873 |
|
Other funds holding CTSO
CM
Northern Trust's CTSO Position: Q2 2026 in Review
Northern Trust increased its Cytosorbents Corp (CTSO) stake by 21% in Q2 2026, buying an estimated $10.1K and bringing the position to 5,583 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4288.
Northern Trust first reported a position in CTSO in Q1 2015 and has held it in 46 quarters since. The position peaked at $4.66M in Q3 2018. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Northern Trust held 5,583 shares of Cytosorbents Corp worth $41.8K as of Q2 2026.
- Northern Trust bought 956 Cytosorbents Corp shares in Q2 2026, an estimated $10.1K.
- Cytosorbents Corp made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4288 holding.
- Northern Trust first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 46 quarters since.
- Northern Trust's Cytosorbents Corp position peaked at $4.66M in Q3 2018.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.